Skip to content
Study details
Enrolling now

ReACT Study

Jonathan Schoenfeld, MD, MPH
NCT IDNCT04900623ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

145

Study length

about 11 years

Ages

22+

Locations

2 sites in MA

What this study is about

This trial is testing if a personalized treatment plan can be created for people with HPV-related oropharyngeal cancers. The treatment plan uses information about the cancer stage and a blood test to check for HPV DNA. Participants will receive chemotherapy, radiation therapy, and/or NavDx® HPV ctDNA testing.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Radiotherapy
  • 2.Take Chemotherapy drug
  • 3.Use NavDx HPV ctDNA Testing

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Progression Free Survival 2 Years

Secondary: Best Overall Response, Overall Survival at 2 Years, Safety and Toxicity

Procedures

radiation

Body systems

Oncology